Cyclo Therapeutics (Cyclo Therapeutics) Cash-to-Debt : 8.95 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cyclo Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.95.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cyclo Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cyclo Therapeutics's Cash-to-Debt or its related term are showing as below:

CYTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.5 Med: 81.51 Max: No Debt
Current: 8.95

During the past 13 years, Cyclo Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.50. And the median was 81.51.

CYTH's Cash-to-Debt is ranked better than
76.12% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs CYTH: 8.95

Cyclo Therapeutics Cash-to-Debt Historical Data

The historical data trend for Cyclo Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cyclo Therapeutics Cash-to-Debt Chart

Cyclo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

53.54

65.88

97.15

No Debt

8.95

Cyclo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	16.94	17.18	40.04	8.95

Competitive Comparison of Cyclo Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclo Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Cash-to-Debt falls into.

Cyclo Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cyclo Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.247	/	(1.011	+	0.022)
	=	8.95

Cyclo Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.247	/	(1.011	+	0.022)
	=	8.95

Cyclo Therapeutics (NAS:CYTH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cyclo Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

Executives

Vivien Wong	director	6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc.	10 percent owner	520 BROAD STREET, NEWARK NJ 07120
William Conkling	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate	director, officer: Chief Executive Officer	C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic	director	932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger	director	BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine	director	600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow	officer: SVP for Medical Affairs	4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems	officer: Chief Medical Officer	91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine	officer: Chief Financial Officer	21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak	officer: Chief Regulatory Officer	12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit,	10 percent owner	966 HUNGERFORD DRIVE, ROCKVILLE MD 20850